Physician profile
Michael Bryan
NPI 1356443196
$9,603.08
in general payments reported to CMS, 2019-2025
36 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,239 · 2020: $667 · 2021: $870 · 2022: $1,315 · 2023: $1,551 · 2024: $1,593 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,352 · Education: $160.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,351.72 |
| Education | $159.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,441.37 | 2019-2025 | Skyrizi, Rinvoq |
| Ucb, INC. | $1,351.06 | 2019-2025 | Bimzelx |
| Janssen Biotech, INC. | $935.95 | 2019-2025 | Tremfya, Remicade, Stelara |
| Novartis Pharmaceuticals Corporation | $820.48 | 2019-2024 | |
| Amgen INC. | $643.50 | 2019-2025 | Otezla, Otezla, Enbrel |
| Dermavant Sciences, INC. | $461.02 | 2022-2024 | Vtama |
| Genzyme Corporation | $424.99 | 2020-2025 | |
| Pfizer INC. | $392.76 | 2019-2025 | |
| Incyte Corporation | $276.55 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $215.43 | 2021-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $189.49 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $142.84 | 2021-2025 | Absorica Ld, Winlevi |
| Galderma Laboratories, L.P. | $138.49 | 2019-2025 | Nemluvio, Epsolay, Twyneo |
| Revance Therapeutics, INC. | $115.12 | 2025 | Daxxify |
| Vyne Pharmaceuticals INC. | $105.92 | 2020 |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bryan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.